menu
    • menu
    [{"orgOrder":0,"company":"NanoTx Therapeutics","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoTx Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"NanoTx Therapeutics \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NanoTx Therapeutics \/ Plus Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Pharma Solutions \/ Plus Therapeutics"},{"orgOrder":0,"company":"Biocept Inc","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocept Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocept Inc \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Biocept Inc \/ Plus Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Rhenium-186

    Menu

    Rhenium-186

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocept Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Biocept Inc

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

                            Details : The agreement will employ Biocept’s cerebrospinal fluid assay CNSide1 in Plus Therapeutics’ ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), which is cancer in the membrane...

                            Brand Name : 186RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 22, 2022

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual ...

                            Details : In preclinical and clinical trials of 186RNL for treating GBM, ReSPECT-GBM, we delivered up to 20x the absorbed dose of radiation versus standard external beam radiation therapy (EBRT), successfully reducing tumors without significant toxicity.

                            Brand Name : Rhenium NanoLiposome

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Piramal Pharma Solutions

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Piramal Pharma Solutions

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.

                            Details : The two Companies envision that the MSA will lead to clinical and commercial supply agreements for the drug product 186RNL (rhenium liposome) at the appropriate stage of development.

                            Brand Name : 186RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 23, 2021

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial

                            Details : Rhenium NanoLiposome (RNL™) is designed to safely, effectively and conveniently deliver a very high dose of radiation potentially up to 15 times greater than traditional external beam radiation therapy.

                            Brand Name : 186RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

                            Details : University of Texas MD Anderson Cancer Center is now an active clinical trial site in Plus Therapeutics' ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI).

                            Brand Name : BMEDA-Chelated Rhenium NanoLiposome

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblas...

                            Details : Investigational drug RNL™ delivers up to fifteen times the absorbed dose of radiation compared to standard external beam radiation therapy.

                            Brand Name : RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 19, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial

                            Details : Plus Therapeutics has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of rec...

                            Brand Name : RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting

                            Details : Plus Therapeutics' abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.

                            Brand Name : RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 01, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Plus Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Plus Therapeutics Receives Fast Track Designation from FDA for Its Novel Glioblastoma Treatment

                            Details : RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation, of up to 25 times greater concentration than currently used external beam radiation therapy, directly into the brain tumor for maximum effect.

                            Brand Name : RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NanoTx Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            NanoTx Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : $137.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Plus Therapeutics Announces Closing of Agreement to License Novel Oncology Platform with NanoTx Therapeutics

                            Details : Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $0.4 million

                            May 11, 2020

                            Lead Product(s) : Rhenium-186

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : $137.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth